Skip to main content

Table 1 Grade 3 to 5 adverse events of special interest in patients aged ≥70 years versus patients aged <70 years in the ATHENA trial (Biganzoli et al. 2012 ) [Permission required for reproduction]

From: The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?

  Age <70 years (n = 2,076), % Age ≥70 years (n = 175), %
  On treatment Entire study period On treatment Entire study period
Hypertension 3.2 4.2 5.1 6.9
 Grade 3 3.1 4.0 4.6 6.3
 Grade 4 <0.1 0.1 0.6 0.6
ATE/VTE 1.2 3.3 0.6 2.9
 Grade 3 1.2 2.4 0.6 0.6
 Grade 4 0 0.7 0 1.7
 Grade 5 0 0.2 0 0.6
Proteinuria 1.0 1.5 2.3 4.0
 Grade 3 1.0 1.4 2.3 2.9
 Grade 4 0 0.1 0 1.1
Other hemorrhage 0.3 1.4 1.1 1.1
 Grade 3 0.2 1.1 1.1 1.1
 Grade 4 <0.1 0.2 0 0
 Grade 5 0 0.1 0 0
Wound healing complications 0.3 0.6 0.6 1.1
 Grade 3 0.2 0.3 0 0.6
 Grade 4 0.1 0.2 0.6 0.6
Congestive heart failure 0.1 0.4 0 0.6
 Grade 3 0.1 0.3 0 0
 Grade 4 <0.1 <0.1 0 0
 Grade 5 0 0.1 0 0.6
Gastrointestinal perforation 0 0.3 0 0
 Grade 3 0 0.1 0 0
 Grade 4 0 <0.1 0 0
 Grade 5 0 0.1 0 0
Fistulae 0 0.1 0 0
 Grade 3 0 0.1 0 0
CNS bleeding 0 <0.1 0 0
 Grade 5 0 <0.1 0 0
  1. AVE/VTE arterial or venous thromboembolism, CNS central nervous system.